Long-term update of the 24954 EORTC phase III trial on larynx preservation

Eur J Cancer. 2016 Sep:65:109-12. doi: 10.1016/j.ejca.2016.06.024. Epub 2016 Aug 2.

Abstract

The long-term results of the EORTC 24954 trial comparing sequential versus alternating chemotherapy and radiotherapy (RT) for patients with locally advanced laryngeal and hypopharyngeal cancer are reported. From 1996 to 2004, 450 patients were randomly assigned (1-1) to a sequential arm (SA = induction cisplatin-5fluorouracil followed by a 70Gy-RT for the responders or a total laryngectomy and post-operative RT for the non-responders) and an alternating arm (AA = cisplatin-5fluorouracil alternated with three 2-week courses of 20 Gy-RT for a total dose of 60 Gy). Median follow-up was 10.2 years. Ten-year survival with functional larynx (primary end-point) and overall survival were similar in both arms (18.7% and 33.6% in SA versus 18.3% and 31.6% in AA). Late toxicity was also similar; however, a trend for higher larynx preservation and better laryngeal function was observed in AA.

Keywords: Larynx preservation; Late toxicity; Radiochemotherapy.

Publication types

  • Clinical Trial, Phase III
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / therapy*
  • Chemoradiotherapy / methods*
  • Cisplatin / administration & dosage
  • Disease Progression
  • Dose Fractionation, Radiation
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Hypopharyngeal Neoplasms / pathology
  • Hypopharyngeal Neoplasms / therapy*
  • Laryngeal Neoplasms / pathology
  • Laryngeal Neoplasms / therapy*
  • Laryngectomy
  • Larynx*
  • Male
  • Middle Aged
  • Organ Sparing Treatments / methods*
  • Survival Analysis
  • Young Adult

Substances

  • Cisplatin
  • Fluorouracil